Target intelligence / Profile preview

Sodium-coupled neutral amino acid transporter 1 (SLC38A1)

Target
SLC38A1
Molecular classification
Transporter, Solute carrier family, Sodium-coupled neutral amino acid transporter, Membrane protein
01

Overview

Sodium-coupled neutral amino acid transporter 1 (SLC38A1, SNAT1) is a membrane-bound transporter belonging to the solute carrier (SLC) family 38. It mediates the uptake of small neutral amino acids, with a predominant role in glutamine import. SLC38A1 functions using a sodium-dependent mechanism and is expressed in numerous human tissues such as the brain, testis, placenta, endocrine organs, and gastrointestinal tract. In cancer cells, SNAT1 is often upregulated to meet increased nutrient requirements, thereby supporting proliferation, migration, and invasion, and preventing senescence. SNAT1 also regulates metabolic and signaling pathways, including mTORC1 activation and glutathione synthesis, critical for cell survival and growth. Its inhibition (e.g., via MeAIB) can suppress tumor cell proliferation, highlighting its status as a potential therapeutic target for cancer and other metabolic or neurological diseases

Other names
SNAT1ATA1NAT2SAT1Amino acid transporter A1System A amino acid transporter 1System N amino acid transporter 1Sodium-coupled neutral amino acid symporter 1N-system amino acid transporter 2
02

Mechanism of action

Competitive inhibition of amino acid transport (e.g., MeAIB blocks SNAT1-mediated glutamine and neutral amino acid uptake)

03

Biological functions

Amino acid transport (mainly small neutral amino acids, especially glutamine)Regulation of cell proliferationCellular migration and invasionInhibition of cellular senescenceActivation of mTOR signaling pathwaySupport of glutathione synthesis and ROS detoxificationInflux/efflux of amino acids in various tissues (brain, testis, placenta, endocrine, respiratory, GI tract)
04

Disease associations

Cancer (notably melanoma, osteosarcoma, breast cancer, hepatocellular carcinoma)Neurodegenerative diseasesMetabolic diseasesImmune diseases
05

Safety considerations

Potential off-target effects due to broad tissue expressionRisk of disrupting amino acid homeostasis and cellular metabolismPossibility of neurotoxicity or metabolic side effects due to inhibition in non-tumor tissues
06

Interacting drugs

α-(methylamino)isobutyric acid (MeAIB)
07

Biomarkers

Overexpression in melanoma and other tumors is associated with proliferative potential and poor prognosis

Beyond the preview

Go deeper on Sodium-coupled neutral amino acid transporter 1 (SLC38A1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sodium-coupled neutral amino acid transporter 1 (SLC38A1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call